ArticleBiomarker research2025

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.

Narendranath Epperla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.